Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report)’s share price fell 24.6% during mid-day trading on Tuesday . The company traded as low as $0.8296 and last traded at $0.8296. 772 shares changed hands during trading, a decline of 79% from the average daily volume of 3,614 shares. The stock had previously closed at $1.10.
Vaccinex Trading Down 24.6%
The company has a market cap of $2.16 million, a price-to-earnings ratio of -0.02 and a beta of 1.10. The firm’s 50-day moving average price is $1.02 and its 200 day moving average price is $1.02.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Featured Articles
- Five stocks we like better than Vaccinex
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
